News & Events
Media Articles
“The Little Fish that May Change a Big Industry: Znomics moves to revolutionize drug discovery as we know it”,
by Anthony A. Haddad, Equities Magazine, September 2008
Latest News Releases
December 10 , 2008
Znomics CEO Mark Philip sends letter to shareholders
[Read the complete letter...]
October 13, 2008
Znomics Builds Patent Estate for Proprietary Zebrafish Technologies
Znomics announced that it has reached a significant research development milestone resulting in the company seeking patent protection for its proprietary zebrafish technologies. [Read the complete press release...]
October 13, 2008
Znomics Announces Purchase of $50,000 of Its Common Stock by Directors and Officers
Znomics announced that it has agreed to sell, and certain officers and directors of the company agreed to purchase, the number of shares equal to the aggregate offering price of $50,000 divided by the last sale price of the company's common stock on October 16, 2008. [Read the complete press release...]
August 25, 2008
Znomics Appoints Ofir Moreno, Ph.D., as Senior Director of Chemistry
Znomics announced today that it has named Ofir Moreno, Ph.D., as the company's new senior director of chemistry. Dr. Moreno is a leading medicinal chemist with more than 14 years of experience in the pharmaceutical industry and a rare track record of successful drug discovery. He has held research positions at Merck, Amgen, Corvas International, and Dendreon where he served as senior director of chemistry. [Read the complete press release...]
August 15, 2008
Znomics Appoints Mark. A. Philip, Ph.D., as New President and Chief Executive Officer
Znomics announced the appointment of Mark A. Philip, Ph.D. as the company’s new president and chief executive officer, effective August 14. Dr. Philip succeeds Richard Sessions, Znomics co-founder and interim CEO, who will remain as a consultant to the company and as an active member of Znomics’ board of directors. [Read the complete press release...]
July 9, 2008
Znomics and Leading Chemist at Oregon Health & Science University Launch Drug Discovery Program for Treatment of Inflammatory Diseases
Znomics announced today a collaborative research program with Oregon Health & Science University (OHSU) and Thomas Scanlan, Ph.D., Director of its Chemical Biology Program, to design and develop pre-clinical compounds to treat diseases such as rheumatoid arthritis, asthma and inflammatory bowel syndrome. [Read the complete press release...]
June 11, 2008
Znomics Appoints Pharmaceutical Drug Discovery Expert, Bruce A. Beutel, Ph.D., as New Chief Scientific Officer
Znomics announced that it has named Bruce A. Beutel, Ph.D. as the company's new chief scientific officer, succeeding Roger Cone, Ph.D. Dr. Cone has accepted the position of chairman of the Department of Molecular Physiology and Biophysics at Vanderbilt University Medical Center, starting in August, but will continue as a scientific consultant to Znomics and as an active member of the company's board of directors. Dr. Beutel's appointment is effective June 16, 2008. [Read the complete press release...]
May 8, 2008
Znomics and University of Utah Launch Collaborative Drug Discovery Program
Znomics announced a collaborative research program with the University of Utah and its Huntsman Cancer Institute (HCI) to develop pre-clinical compounds for the treatment of T-cell leukemia, autoimmune diseases, inflammation and complications related to organ transplantation. [Read the complete press release...]
April 16, 2008
Znomics Launches Drug Discovery Program in Obesity Using Proprietary In Vivo Screening Model
Znomics announced the launch of a program to find lead drug compounds for the treatment of obesity. [Read the complete press release...]
March 6, 2008
Znomics Appoints Stephane Berghmans, D.V.M., Ph.D. to Director of Drug Discovery
Znomics announced the appointment of Stephane Berghmans, D.V.M., Ph.D. to Director of Drug Discovery, effective March 10, 2008. [Read the complete press release...]
February 25, 2008
Znomics Expands Drug Discovery Facilities
Znomics announced that it has expanded its facilities to include additional laboratory space in the new Biomedical Research Building on the campus of Oregon Health and Science University (OHSU) in Portland. [Read the complete press release...]
February 14, 2008
Znomics Promotes Stephen Kurtz, Ph.D. to Director of Operations
Znomics announced the promotion of Stephen Kurtz, Ph.D. to director of operations, effective March 1, 2008. As director of operations, reporting to the chief executive officer and chief scientific officer, Kurtz will be responsible for expanding Znomics’ drug discovery program by evaluating new technologies, at universities and companies, for possible in-licensing opportunities. Additionally, he will oversee some laboratory operations as well as liaise with university and corporate scientists that engage in collaborative programs with Znomics. [Read the complete press release...]
February 12, 2008
Znomics Retains James Posada as Business Advisor
Znomics announced that it has retained James Posada, Ph.D., as a business advisor to assist with business development, effective immediately. Posada’s initial mission will be to help with the development of collaborative programs with potential pharmaceutical and biotechnology partners. Additionally, he will oversee technology in-licensing and out-licensing activities for Znomics. [Read the complete press release...]
February 6, 2008
Znomics Advances Drug Discovery Efforts in Zebrafish With Launch of New Human Disease Library
Znomics announced that it has achieved mutations in 193 key genes, representing nearly 50 percent of the known “druggable” disease genes. The company expects that information derived from these disrupted genes and others from its ZeneMark® library of mutant fish lines will advance its search for new drug targets and new lead compounds for complex human diseases. [Read the complete press release...]
January 23, 2008
Znomics Appoints Thomas Scanlan, Professor of Pharmacology, to Scientific Advisory Board
Professor Scanlan’s leading work in drug compound discovery and biological research has been recognized by the American Chemical Society, which awarded him the prestigious Arthur C. Cope Scholar Award in July, 2007. His appointment expands Znomics’s SAB to five members. [Read the complete press release...]
January 4, 2008
Znomics, Inc. Begins Trading Under New Ticker Symbol -- ZNOM.OB
Znomics announced that its common stock will begin trading on the OTC Bulletin Board under the new ticker symbol, “ZNOM.OB”, effective today, Friday, January 4, 2008. [Read the complete press release...]
© Copyright Znomics, Inc. All rights reserved.